The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Thiamethoxam results in increased activity of ALPL protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of ALPL protein]
Thiamethoxam results in increased expression of CAT mRNA Thiamethoxam results in decreased expression of CAT mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of CAT mRNA]
Thiamethoxam results in decreased expression of CYP11A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of CYP11A1 mRNA]
Thiamethoxam results in increased expression of CYP19A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of CYP19A1 mRNA] Thiamethoxam results in increased activity of CYP19A1 protein
Thiamethoxam results in increased activity of GOT1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GOT1 protein]
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GPX1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of GPX1 mRNA] Thiamethoxam results in increased expression of GPX1 mRNA
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of IL1B protein] Thiamethoxam results in increased expression of IL1B mRNA; Thiamethoxam results in increased expression of IL1B protein
Thiamethoxam results in increased activity of LDHA protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of LDHA protein]
Thiamethoxam results in decreased expression of LHCGR protein Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of LHCGR mRNA]
Thiamethoxam results in increased expression of NOS2 mRNA Silymarin inhibits the reaction [Thiamethoxam results in increased expression of NOS2 mRNA] Thiamethoxam metabolite results in decreased activity of NOS2 protein [Thiamethoxam metabolite results in decreased activity of NOS2 protein] which results in increased chemical synthesis of Formaldehyde
Thiamethoxam results in decreased activity of SOD1 protein Thiamethoxam results in decreased expression of SOD1 mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of SOD1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of SOD1 mRNA]
Thiamethoxam results in decreased expression of STAR mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of STAR mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF protein] Thiamethoxam results in increased expression of TNF mRNA; Thiamethoxam results in increased expression of TNF protein
Thiamethoxam results in increased secretion of TNNT2 protein fenugreek seed meal inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]; Polysaccharides inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in increased expression of BAX protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in increased expression of CASP3 protein] N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Colchicine results in increased activity of CASP3 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in increased expression of CASP9 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in decreased expression of CCNB1 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in decreased expression of CCND1 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in decreased expression of CCNE1 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in decreased expression of CDK2 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [troglitazone results in decreased expression of CDK4 protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNB1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCND1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNE1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK2 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK4 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of BAX protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP3 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP9 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Okadaic Acid; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Proadifen; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in increased susceptibility to Troglitazone; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of GSK3B protein]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]
[N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA] benphothiamine metabolite results in increased expression of GCLM mRNA; benphothiamine results in increased expression of GCLM mRNA
benphothiamine metabolite results in increased expression of HMOX1 mRNA; benphothiamine results in increased expression of HMOX1 mRNA benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]
benphothiamine results in decreased phosphorylation of MAPT protein [benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein; [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; [benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA; benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein]; benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA]
[benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA]
benphothiamine metabolite results in increased expression of NQO1 mRNA; benphothiamine results in increased expression of NQO1 mRNA [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA]
[benphothiamine co-treated with Streptozocin] results in increased activity of TKT protein benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]
SLC22A8 protein results in increased uptake of cefoselis cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]
Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]
Ceftriaxone results in decreased expression of CAT protein Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]]
ceftriaxone increases expression of Slc1a2 protein in prefrontal cortex and nucleus accumbens [ceftriaxone co-treated with ethanol] results in increased expression of Slc1a2 protein in prefrontal cortex and nucleus accumbens Ceftriaxone cotreated with ethanol increases expression of Slc1a2 protein in nucleus accumbens, amygdala and prefrontal cortex Ceftriaxone cotreated ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex ceftriaxone inhibits the reaction [ethanol decreases expression of Slc1a2 protein in the shell of nucleus accumbens] ceftriaxone increases expression of Slc1a2 protein in hippocampus Ceftriaxone inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [JZL195 results in decreased expression of and affects the folding of SLC1A2 protein]; Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein] Ceftriaxone results in increased expression of SLC1A2 protein
Ceftriaxone cotreated with ethanol increases expression of Slc7a11 protein in nucleus accumbens, amydgala and prefrontal cortex Ceftriaxone increases expression of Slc7a11 protein in dorsal striatum [ceftriaxone co-treated with ethanol] results in increased expression of Slc7a11 protein in prefrontal cortex and nucleus accumbens Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC7A11 protein]
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]
[enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA clothianidin results in increased expression of ABCC3 mRNA
clothianidin results in increased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA
clothianidin results in decreased expression of CHRNA7 mRNA clothianidin results in increased activity of CHRNA7 protein; clothianidin results in increased activity of CHRNA7 protein mutant form
clothianidin results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; clothianidin results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein] clothianidin promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
[clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA clothianidin results in increased expression of CYP1A2 mRNA
clothianidin results in increased expression of CYP2B2 mRNA [enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA
clothianidin results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA
clothianidin results in increased expression of CYP3A4 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA clothianidin results in increased expression of CYP3A23-3A1 mRNA
[clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA clothianidin results in increased expression of CYP3A5 mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA clothianidin results in decreased expression of CYP7A1 mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA clothianidin results in decreased expression of ELN mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA clothianidin results in decreased expression of KY mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA clothianidin results in decreased expression of MEGF11 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA clothianidin results in increased expression of MME mRNA
clothianidin results in decreased expression of SLC6A1 mRNA [enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA
clothianidin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; clothianidin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of HSPA5 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat
[BRAF protein affects the susceptibility to dabrafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] dabrafenib results in decreased activity of BRAF protein; dabrafenib results in decreased activity of BRAF protein mutant form
dabrafenib results in increased expression of CYP3A4 mRNA dabrafenib inhibits the reaction [CYP3A4 protein results in decreased susceptibility to Docetaxel] dabrafenib results in decreased activity of CYP3A4 protein
dabrafenib inhibits the reaction [Polyphosphates results in increased expression of ICAM1 mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of ICAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of ICAM1 protein]
dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [ITGAV protein binds to ITGB5 protein]]
dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [ITGAV protein binds to ITGB5 protein]]
KRAS protein affects the susceptibility to dabrafenib [KRAS protein affects the susceptibility to dabrafenib] which affects the expression of TNFRSF10B protein; [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK1 protein; [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK3 protein
dabrafenib results in decreased phosphorylation of MAP2K1 protein decabromobiphenyl ether inhibits the reaction [dabrafenib results in decreased phosphorylation of MAP2K1 protein]
dabrafenib results in decreased phosphorylation of MAPK1 protein dabrafenib results in increased phosphorylation of MAPK1 protein [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK1 protein; dabrafenib inhibits the reaction [Polyphosphates results in increased phosphorylation of MAPK1 protein]; decabromobiphenyl ether inhibits the reaction [dabrafenib results in decreased phosphorylation of MAPK1 protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; SRPIN340 inhibits the reaction [dabrafenib results in increased phosphorylation of MAPK1 protein]
[KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK3 protein; dabrafenib inhibits the reaction [Polyphosphates results in increased phosphorylation of MAPK3 protein]; decabromobiphenyl ether inhibits the reaction [dabrafenib results in decreased phosphorylation of MAPK3 protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; SRPIN340 inhibits the reaction [dabrafenib results in increased phosphorylation of MAPK3 protein]
dabrafenib inhibits the reaction [Polyphosphates results in increased expression of SELE mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of SELE protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of SELE protein]
dabrafenib results in decreased cleavage of SREBF1 protein [BRAF protein affects the susceptibility to dabrafenib] which affects the cleavage of SREBF1 protein
dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TGFBI mRNA]; dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TGFBI protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of ICAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of SELE protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of VCAM1 protein]
dabrafenib inhibits the reaction [Polyphosphates results in increased expression of VCAM1 mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of VCAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of VCAM1 protein]
dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of perrhenate analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Pertechnetate Tc 99m]
epothilone A results in increased expression of CASP3 mRNA [epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA; Sodium Salicylate promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA]; triciribine promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA]
[epothilone A co-treated with Metformin] results in increased expression of PARP1 mRNA; Sodium Salicylate inhibits the reaction [epothilone A results in increased expression of PARP1 mRNA]; triciribine inhibits the reaction [epothilone A results in increased expression of PARP1 mRNA]; triciribine promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of PARP1 mRNA]
epothilone B results in decreased expression of CALCA protein epothilone B affects the reaction [[Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein]; epothilone B inhibits the reaction [Potassium results in increased secretion of CALCA protein]; epothilone B promotes the reaction [[Potassium co-treated with NGF protein] results in increased secretion of CALCA protein]
epothilone B affects the reaction [[Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein]; epothilone B promotes the reaction [[Potassium co-treated with NGF protein] results in increased secretion of CALCA protein]
Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of CAT protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]] Famotidine inhibits the reaction [Indomethacin results in decreased expression of CAT protein]
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CTNNB1 mRNA] Famotidine results in increased expression of CTNNB1 mRNA
Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]]
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]]
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]]
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]]
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Famotidine inhibits the reaction [Dizocilpine Maleate results in increased expression of GSK3B mRNA]
[Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Famotidine binds to and results in decreased activity of HRH2 protein; Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA] Famotidine results in decreased activity of HRH2 protein [Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Histamine Famotidine results in increased expression of HRH2 protein
Famotidine results in decreased expression of HSPA1A protein Zinc Compounds analog inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein]
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]] Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]
Famotidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]
[Famotidine co-treated with Sucralfate] results in decreased expression of IL1B mRNA Famotidine inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of IL1B mRNA]
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]
Famotidine inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of IL6 protein]
Famotidine inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; Famotidine inhibits the reaction [Histamine results in increased secretion of MMP1 protein]
Famotidine inhibits the reaction [Ethanol results in increased expression of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased expression of MMP9 mRNA]; Famotidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of MMP9 protein]
Famotidine inhibits the reaction [Acids results in increased activity of MPO protein] Famotidine inhibits the reaction [Ethanol results in increased activity of MPO protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]; Famotidine promotes the reaction [Chlorpheniramine results in decreased activity of MPO protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]] Famotidine results in increased expression of MPO protein
[Pyrilamine co-treated with Famotidine co-treated with ciproxifan] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; [Pyrilamine co-treated with Famotidine] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; Famotidine inhibits the reaction [Histamine results in increased expression of NTF3 protein]
[Famotidine co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Famotidine promotes the reaction [Acetic Acid results in increased expression of PCNA protein]
Famotidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA] Famotidine inhibits the reaction [Indomethacin results in decreased expression of PTGS2 mRNA]
Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] SLC19A3 protein results in increased uptake of Famotidine
Famotidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein results in increased uptake of Famotidine SLC22A1 protein affects the transport of Famotidine
SLC22A2 protein results in increased uptake of Famotidine Famotidine inhibits the reaction [SLC22A2 protein affects the transport of Tetraethylammonium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Famotidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Famotidine results in decreased activity of SLC22A3 protein
estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Famotidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Famotidine results in increased secretion of TNF protein Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]] Famotidine inhibits the reaction [Ethanol results in increased expression of TNF protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of TNF protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of TNF mRNA]
Febuxostat inhibits the reaction [Paraquat results in decreased secretion of AGER protein modified form]; Febuxostat inhibits the reaction [Paraquat results in increased expression of AGER mRNA]
Febuxostat inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) co-treated with Freund's Adjuvant] results in decreased expression of GOT2 mRNA]; Febuxostat inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) co-treated with Freund's Adjuvant] results in decreased expression of GOT2 protein]
Febuxostat inhibits the reaction [Estradiol results in increased expression of VEGFA protein]; Febuxostat inhibits the reaction [Paraquat results in increased expression of VEGFA protein]
GW 501516 inhibits the reaction [APP gene mutant form results in decreased expression of GCH1 protein]; GW 501516 inhibits the reaction [APP gene mutant form results in decreased expression of SOD1 protein]; GW 501516 inhibits the reaction [APP gene mutant form results in decreased expression of SOD3 protein]; GW 501516 inhibits the reaction [APP gene mutant form results in decreased phosphorylation of NOS3 protein]; GW 501516 inhibits the reaction [APP gene mutant form results in decreased susceptibility to Acetylcholine]; GW 501516 inhibits the reaction [APP gene mutant form results in increased abundance of 7,8-dihydrobiopterin]; GW 501516 inhibits the reaction [APP gene mutant form results in increased chemical synthesis of Superoxides]; GW 501516 inhibits the reaction [APP gene mutant form results in increased expression of CYBB protein]; GW 501516 inhibits the reaction [APP gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of SELE mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA] GW 501516 results in decreased expression of CCL2 mRNA GW 501516 inhibits the reaction [Palmitates results in increased expression of CCL2 mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of IL1B mRNA] GW 501516 results in decreased expression of IL1B mRNA
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; PPARD mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]
GW 501516 results in increased expression of NR1H3 mRNA NR1H3 protein affects the susceptibility to GW 501516 NR1H3 protein affects the reaction [GW 501516 results in increased expression of PPARA mRNA]
[GW 501516 binds to PPARD protein] which results in increased expression of PLIN2 mRNA; PPARD mutant form inhibits the reaction [GW 501516 results in increased expression of PLIN2 mRNA]
[Calcitriol co-treated with GW 501516] results in increased expression of PPARA mRNA; NR1H3 protein affects the reaction [GW 501516 results in increased expression of PPARA mRNA] PPARA protein affects the susceptibility to GW 501516 GW 501516 binds to PPARA protein
GW 501516 binds to PPARB protein; GW 501516 binds to PPARD protein GW 501516 results in increased expression of PPARD mRNA GW 501516 results in increased activity of PPARD protein [GW 501516 binds to PPARD protein] inhibits the reaction [Phenylephrine results in increased activity of RELA protein]; [GW 501516 binds to PPARD protein] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; [GW 501516 binds to PPARD protein] inhibits the reaction [Phenylephrine results in increased expression of NPPB mRNA]; MDM2 protein inhibits the reaction [GW 501516 results in increased activity of PPARB protein] [Calcitriol co-treated with GW 501516] results in increased expression of PPARD mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of ABHD3 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of ACADM mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of ACADVL mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of ANGPTL4 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of CEBPA mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of CPT1A mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of DDIT4 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of ECH1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of FABP1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of HADHA mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of HMGCS2 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of HSDL2 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of KIZ mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of LIPC mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of NEDD9 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of PCK1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of PDZK1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of PLIN2 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of PLTP mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of RNU7-65P mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of SERPINE1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of SLC22A7 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of SLC30A10 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of SULT2A1 mRNA; [GW 501516 binds to PPARD protein] which results in increased expression of TRIB2 mRNA; GW 501516 binds to and results in increased activity of PPARD protein; GW 501516 promotes the reaction [PPARD protein results in increased expression of SIRT1 mRNA]; PPARD mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; PPARD mutant form inhibits the reaction [GW 501516 results in increased expression of PLIN2 mRNA] 4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide inhibits the reaction [GW 501516 results in increased expression of PPARD mRNA]; [GW 501516 co-treated with PPARD protein] results in increased expression of PPARGC1A mRNA; GW 501516 binds to and results in increased activity of PPARD protein
[GW 501516 binds to PPARD protein] inhibits the reaction [Phenylephrine results in increased activity of RELA protein]; RELA protein inhibits the reaction [GW 501516 results in increased expression of CPT1B mRNA]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of SELE mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of SELE mRNA]
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of SELE mRNA]]; BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; GW 501516 inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; GW 501516 inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; PPARD mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of MMP9 protein]] GW 501516 results in decreased expression of TNF mRNA
BCL6 mutant form inhibits the reaction [GW 501516 inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; GW 501516 inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]
LCL161 binds to and affects the activity of ABCB1 protein; LCL161 inhibits the reaction [ABCB1 protein results in increased export of Fluorescent Dyes]; LCL161 inhibits the reaction [ABCB1 protein results in increased export of mitotracker green FM]
masitinib results in decreased phosphorylation of and results in decreased activity of KIT protein masitinib binds to and results in decreased phosphorylation of and results in decreased activity of KIT protein
masitinib results in increased secretion of TGFB1 protein [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib] results in increased secretion of TGFB1 protein; [masitinib co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein
Meloxicam inhibits the reaction [Doxorubicin results in increased activity of ABCB1 protein]; Meloxicam inhibits the reaction [Doxorubicin results in increased expression of ABCB1 protein]
[Meloxicam co-treated with Cilostazol] results in increased activity of CASP3 protein Meloxicam results in increased activity of CASP3 protein Meloxicam inhibits the reaction [Diquat results in increased expression of CASP3 protein modified form] [Rutin co-treated with Meloxicam] affects the reaction [Formaldehyde affects the expression of CASP3 protein]; Meloxicam affects the reaction [Formaldehyde affects the expression of CASP3 protein]; Meloxicam inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
Meloxicam inhibits the reaction [Diquat results in increased expression of CASP9 protein modified form] Meloxicam results in increased activity of CASP9 protein [Meloxicam co-treated with Cilostazol] results in increased activity of CASP9 protein
Meloxicam results in decreased expression of CAT protein Meloxicam affects the expression of and affects the activity of CAT protein meloxicam inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]
[CYP1A2 protein results in increased metabolism of and results in increased susceptibility to Meloxicam] which results in increased chemical synthesis of Pyruvaldehyde; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to Meloxicam
[meloxicam results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased expression of EREG mRNA]
Meloxicam inhibits the reaction [HMGB1 protein results in increased expression of PTGS2 protein]; Meloxicam inhibits the reaction [HMGB1 protein results in increased phosphorylation of MAPK1 protein]; Meloxicam inhibits the reaction [HMGB1 protein results in increased phosphorylation of MAPK3 protein]; Meloxicam inhibits the reaction [HMGB1 protein results in increased phosphorylation of NFKBIA protein]
[Rutin co-treated with Meloxicam] affects the reaction [Formaldehyde affects the expression of IL1B protein]; Meloxicam affects the reaction [Formaldehyde affects the expression of IL1B protein]
meloxicam results in increased expression of PTGS2 protein meloxicam results in decreased activity of PTGS2 protein Meloxicam inhibits the reaction [Diquat results in increased expression of PTGS2 protein]; Meloxicam inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone] [meloxicam results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [meloxicam results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased expression of EREG mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein] [Meloxicam results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Meloxicam results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Chlorpyrifos; Meloxicam inhibits the reaction [HMGB1 protein results in increased expression of PTGS2 protein]
[Rutin co-treated with Meloxicam] inhibits the reaction [Formaldehyde affects the activity of SORD protein]; Meloxicam inhibits the reaction [Formaldehyde affects the activity of SORD protein]
myxothiazol inhibits the reaction [[Oxygen deficiency results in increased abundance of Reactive Oxygen Species] which results in increased expression of CD36 mRNA]
[Folic Acid deficiency co-treated with succinylsulfathiazole] results in decreased expression of DDIT4 protein succinylsulfathiazole results in increased expression of DDIT4 protein
Ritonavir results in decreased activity of ABCB11 protein Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]
Ritonavir results in decreased expression of ADIPOQ mRNA; Ritonavir results in decreased expression of ADIPOQ protein rosiglitazone inhibits the reaction [Ritonavir results in decreased secretion of ADIPOQ protein] diphenyleneiodonium inhibits the reaction [Ritonavir results in decreased expression of ADIPOQ protein]
diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] Ritonavir results in decreased expression of CCL2
Ritonavir results in increased expression of CDKN1A mRNA; Ritonavir results in increased expression of CDKN1A protein manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of CDKN1A protein]
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]
Ritonavir results in increased expression of CYP3A4 mRNA Ritonavir results in decreased activity of CYP3A4 protein CYP3A4 protein binds to Ritonavir analog CYP3A4 protein affects the metabolism of Ritonavir
Acetylcysteine inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; FTI 277 inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]
Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Bilirubin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]; NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Lopinavir results in increased expression of HMOX1 mRNA]; Rotenone inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; tricarbonyldichlororuthenium (II) dimer promotes the reaction [Ritonavir results in increased expression of HMOX1 protein] Ritonavir results in increased expression of HMOX1 mRNA; Ritonavir results in increased expression of HMOX1 protein
Ritonavir results in increased expression of ICAM1 protein HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]
diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] rosiglitazone inhibits the reaction [Ritonavir results in increased expression of IL6 mRNA] Ritonavir results in increased expression of IL6 mRNA; Ritonavir results in increased expression of IL6 protein
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]
Ritonavir results in increased expression of NFE2L2 protein NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]
Ritonavir results in decreased expression of NOTCH4 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of NOTCH4 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of NOTCH4 protein]
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein] Ritonavir results in increased expression of PPARG mRNA
Ritonavir binds to and affects the localization of PRKCA protein Ritonavir results in increased activity of PRKCA protein Ritonavir results in increased expression of PRKCA protein
Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]
Ritonavir results in decreased expression of TJP1 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of TJP1 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of TJP1 protein]
Ritonavir results in decreased secretion of TNF protein rosiglitazone inhibits the reaction [Ritonavir results in increased expression of TNF mRNA] Ritonavir inhibits the reaction [IFNG protein results in increased secretion of TNF protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Ritonavir results in increased expression of TNF mRNA; Ritonavir results in increased expression of TNF protein
FTI 277 inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of 1700012B07RIKL gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA Thiabendazole results in increased expression of ANGPTL4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA
Thiabendazole results in increased expression of CDKN1A mRNA [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLEC2G mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA
herbimycin inhibits the reaction [Thiabendazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 protein] Thiabendazole results in increased expression of CYP1A1 mRNA; Thiabendazole results in increased expression of CYP1A1 protein
beta-Naphthoflavone promotes the reaction [CYP1A2 protein affects the metabolism of Thiabendazole] Thiabendazole results in increased expression of CYP1A2 mRNA; Thiabendazole results in increased expression of CYP1A2 protein Thiabendazole results in decreased activity of CYP1A2 protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP2C22 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA
Thiabendazole results in increased activity of GCLC protein [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IFNA12L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA Thiabendazole results in increased expression of IGFBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IGKV2-112L2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR193 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of OLR943 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PRSS3B gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SERPINA1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMT1B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UOX mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP455 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of ALPL protein] Thiamethoxam results in increased activity of ALPL protein
Thiamethoxam results in increased expression of CAT mRNA Thiamethoxam results in decreased expression of CAT mRNA Thiamethoxam results in decreased activity of CAT protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of CAT mRNA]
Thiamethoxam results in increased expression of CYP19A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of CYP19A1 mRNA] thiamethoxam results in increased expression of CYP19A1 mRNA thiamethoxam results in increased activity of CYP19A1 protein
Thiamethoxam results in increased activity of GOT1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GOT1 protein]
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GPX1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of GPX1 mRNA] Thiamethoxam results in increased expression of GPX1 mRNA
Thiamethoxam results in decreased expression of HSD3B1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of HSD3B1 mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of IL1B protein] Thiamethoxam results in increased expression of IL1B mRNA; Thiamethoxam results in increased expression of IL1B protein
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of LDHA protein] Thiamethoxam results in increased activity of LDHA protein
Thiamethoxam results in decreased expression of LHCGR protein Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of LHCGR mRNA]
[thiamethoxam metabolite results in decreased activity of NOS2 protein] which results in increased chemical synthesis of Formaldehyde Silymarin inhibits the reaction [Thiamethoxam results in increased expression of NOS2 mRNA]
Thiamethoxam results in decreased activity of SOD1 protein Thiamethoxam results in decreased expression of SOD1 mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of SOD1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of SOD1 mRNA]
Thiamethoxam results in decreased expression of STAR mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of STAR mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF protein] Thiamethoxam results in increased expression of TNF mRNA; Thiamethoxam results in increased expression of TNF protein
Thiamethoxam results in increased secretion of TNNT2 protein fenugreek seed meal inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]; Polysaccharides inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]
Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [Glycerol results in increased secretion of CKM protein]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
[Thiamine deficiency results in increased expression of PTGS2 mRNA] which results in increased expression of Dinoprostone; Thiamine deficiency results in increased expression of PTGS2 mRNA
SLC19A2 protein results in increased uptake of Thiamine [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A2 protein] which results in decreased uptake of Thiamine Thiamine deficiency results in increased expression of SLC19A2 mRNA; Thiamine deficiency results in increased expression of SLC19A2 protein
Thiamine deficiency results in increased expression of SLC19A3 mRNA; Thiamine deficiency results in increased expression of SLC19A3 protein SLC19A3 protein results in increased uptake of Thiamine [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A3 protein] which results in decreased uptake of Thiamine Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Chloroquine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Metformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Phenformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Verapamil inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]
dorsomorphin inhibits the reaction [vosaroxin results in decreased expression of HIF1A protein]; SIRT3 protein inhibits the reaction [vosaroxin results in decreased expression of HIF1A protein]; vosaroxin inhibits the reaction [Oxygen deficiency affects the localization of HIF1A protein]; vosaroxin inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to ARNT protein]]
SIRT2 protein affects the reaction [vosaroxin results in increased activity of IDH2 protein]; SIRT2 protein affects the reaction [vosaroxin results in increased activity of SOD2 protein]
browse the term
